{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"60","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Patients were treated with induction therapy (VRD) followed by autologous hematopoietic cell transplant (AHCT). MRD status of a patient with at least partial response was evaluated at the end of induction (EOI) and day 100 (post-AHCT). MRD of a patient is measured by seven-color flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"VELCADE, Lenalidomide, Dexamethasone\n\nVELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle\n\nLenalidomide: 25 mg by mouth on days 1-4 of each cycle\n\nDexamethasone: 20 mg the day before and the day after receiving VELCADE\n\nDVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice\n\nBisphosphonates: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.","id":"OG000","title":"VELCADE, Lenalidomide, Dexamethasone (VRD)"},{"description":"VELCADE, liposomal doxorubicin, dexamethasone\n\nVELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle\n\nDVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice\n\nLiposomal doxorubicin: 30 mg/m2 on day 4 of each cycle\n\nDexamethasone: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4","id":"OG001","title":"VELCADE, Liposomal Doxorubicin, Dexamethasone (VDD)"}],"paramType":"NUMBER","populationDescription":"Newly diagnosed, symptomatic multiple myeloma (MM) patients. Patients were treated with induction therapy VRD followed by AHCT. MRD staus was evaluated for patients with at least partial response at the end of induction (EOI) therapy. Ten of these patients had MRD negative at EOI.","reportingStatus":"POSTED","timeFrame":"6-months post ASCT","title":"The Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative at Day 100 (Post-AHCT), Among Patients With MRD Positive at the End of Induction (EOI).","type":"PRIMARY","unitOfMeasure":"percentage of participants"}